BRIEF-BridgeBio Says Fortify Phase 3 Study Meets All Primary & Secondary Interim Analysis Endpoints

Reuters
Oct 27
BRIEF-BridgeBio Says Fortify Phase 3 Study Meets All Primary & Secondary Interim Analysis Endpoints

Oct 27 (Reuters) - BridgeBio Pharma Inc BBIO.O:

  • BRIDGEBIO REPORTS POSITIVE PHASE 3 RESULTS FOR SMALL MOLECULE BBP-418 IN LGMD2I/R9 FORTIFY STUDY

  • BRIDGEBIO: FORTIFY PHASE 3 STUDY MEETS ALL PRIMARY & SECONDARY INTERIM ANALYSIS ENDPOINTS

  • BRIDGEBIO: TO FILE NDA FOR APPROVAL WITH FDA IN H1 2026

Further company coverage: BBIO.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10